Русский 
English 
Deutsch 
Español 
العربية 
中文 
Türkçe 
Français 
Italiano 
Major condition groups
Unlike local problems (one disc herniation, one meniscus tear), systemic conditions affect several structures simultaneously or share a common pathogenesis. Osteoarthritis is mechanical cartilage wear with joint space narrowing and osteophyte formation. Arthritis is inflammation of immune or metabolic origin. Tendinitis and bursitis are inflammation of tendons and synovial bursae, often accompanying osteoarthritis. Avascular necrosis is bone tissue ischemia. Osteoporosis is systemic loss of bone density. Below — a detailed breakdown of each group with differential diagnostics.
Osteoarthritis (Arthrosis)
Degenerative cartilage disease — the most common joint condition. Stages I–III. Treatment without joint replacement.
Read more about this condition → M05–M14Arthritis (Systemic)
Rheumatoid, psoriatic, reactive, gouty. Differences from osteoarthritis. Role of MIBRAR® in systemic forms.
Read more about this condition → M77Tendinitis & Tendinopathy
Inflammation and degeneration of tendons: elbow, Achilles, knee, shoulder. Without corticosteroid injections.
Read more about this condition → M71Bursitis
Inflammation of synovial bursae in shoulder, knee, elbow, hip. Aspiration + CGF under ultrasound guidance.
Read more about this condition → M87Avascular Necrosis
Ischemia and bone tissue death (most often femoral head). Decompression + BMAC for joint preservation.
Read more about this condition → M80–M81Osteoporosis
Reduction of bone density. DEXA diagnostics, fracture prevention, role of MIBRAR® in fracture healing.
Read more about this condition →Arthritis vs Osteoarthritis — key differences
These are two fundamentally different conditions that are often confused. Correct differentiation determines the entire treatment scheme — from medication choice to prognosis.
Pain pattern
Osteoarthritis: worsens with load, improves with rest. Evening peak.
Arthritis: persists at rest, often worsens at night and in the morning.
Morning stiffness
Osteoarthritis: 5–30 minutes, "warms up" quickly.
Arthritis: over 60 minutes, sometimes till noon.
Localization
Osteoarthritis: large weight-bearing joints — knee, hip, first MTP, first CMC.
Arthritis: small symmetric joints of the hands, wrists, feet.
Blood tests
Osteoarthritis: ESR, CRP normal.
Arthritis: ESR over 20, CRP elevated, RF or anti-CCP positive (in RA).
X-ray
Osteoarthritis: joint space narrowing, osteophytes, subchondral sclerosis.
Arthritis: periarticular osteoporosis, erosions, ankylosis in late stages.
Treatment
Osteoarthritis: physical therapy, weight loss, MIBRAR®/PRP, prosthesis at stage IV.
Arthritis: disease-modifying therapy (methotrexate, biologics), + MIBRAR® for damaged joints.
Why MIBRAR® for systemic conditions
Autologous method
Uses the patients own cells and growth factors — no risk of allergy, rejection, or immune conflict. Critical in autoimmune forms of arthritis, where the immune system is already overburdened.
Anti-inflammatory effect
CGF contains anti-inflammatory cytokines (IL-1Ra, TGF-β, IL-10) that suppress inflammation directly within the joint — without systemic NSAIDs and corticosteroids, without GI or kidney damage.
Cartilage and bone regeneration
Mesenchymal stem cells (Lipogems®, SVF, BMAC) differentiate into chondrocytes and osteoblasts, restoring damaged cartilage and stimulating bone regeneration in necrosis and osteoporosis.
Compatible with disease-modifying therapy
MIBRAR® does not conflict with methotrexate, biologics (adalimumab, etanercept), denosumab, or bisphosphonates. Only NSAIDs are stopped, 7 days before the procedure.
Ultrasound navigation
Precise targeting of the joint cavity, tendon, or bursa with 1 mm accuracy (Cyber Navi Hand). Critical for deep structures — hip, shoulder, femoral nerve.
Outpatient, no anesthesia
30–60 minute procedure under local anesthesia. Return to normal activity the next day. Sports — after 4–6 weeks. No hospitalization, no rehabilitation center.
Choose the method by your diagnosis
PRP-therapy
Osteoarthritis I–II, tendinitis, mild bursitis. 2–3 procedures with 3–4 week intervals. Learn more →
CGF + Lipogems®
Osteoarthritis II–III, chronic tendinopathy, rheumatoid arthritis (locally), bursitis. The main MIBRAR® protocol.
BMAC
Avascular necrosis, osteoporotic fractures, severe stage III osteoarthritis. Bone marrow concentrate contains hematopoietic and mesenchymal cells. Stem cells →
Frequently asked questions
Osteoarthritis is mechanical cartilage breakdown (wear), while arthritis is inflammation of immune or metabolic origin. Osteoarthritis usually affects 1–2 joints (knee, hip), arthritis affects multiple symmetric small joints. Morning stiffness in osteoarthritis lasts under 30 minutes, in arthritis over 60 minutes. Tests: arthritis shows elevated ESR, CRP, RF, anti-CCP — in osteoarthritis these are normal. Treatment differs fundamentally.
Complete restoration of cartilage to its original state is not yet possible. However, progression can be halted and pain significantly reduced. MIBRAR® at stages I–II achieves full cartilage regeneration to its original state; at stage III it reduces pain and delays joint replacement by 5–10 years. Stage IV is an indication for prosthesis.
Corticosteroids provide rapid relief (2–4 weeks), but with repeated use they damage cartilage, weaken tendons, and cause osteoporosis and avascular necrosis. The FDA recommends no more than 3 injections per year per joint. MIBRAR® uses only autologous growth factors and stem cells — without steroids.
Forms of arthritis where the immune system attacks the joints own tissues. Rheumatoid arthritis (RF, anti-CCP antibodies), psoriatic (with skin psoriasis), ankylosing spondylitis (HLA-B27). Treatment is disease-modifying therapy (methotrexate, biologics) under a rheumatologist. MIBRAR® complements it by regenerating already-damaged joints.
Minimum: ESR, CRP, complete blood count, rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), uric acid, HLA-B27, ANA. If needed — joint puncture with synovial fluid analysis. Doppler ultrasound of joints detects active synovitis.
Very. Without treatment, necrosis progresses over 6–18 months to bone collapse (most often the femoral head) and requires joint replacement. At early stages (ARCO I–II), decompression + injection of bone marrow concentrate (BMAC) restores blood supply and preserves the joint in 70–80% of cases. Early MRI is the key success factor.
Confirm with DEXA scan (T-score below -2.5). Assess risk factors (age, sex, prior fractures, corticosteroids, smoking). Treatment: calcium + vitamin D, bisphosphonates or denosumab, strength exercises, fall prevention. For fractures, MIBRAR® accelerates consolidation through BMAC injection into the fracture site.
Yes, this is the optimal combination. Disease-modifying therapy (methotrexate, biologics) suppresses systemic inflammation. MIBRAR® locally regenerates already-damaged joints. NSAIDs are stopped 7 days before MIBRAR®; disease-modifying therapy continues unchanged. Always coordinated with the treating rheumatologist.
Send your MRI for a free evaluation
Prof. Babayan personally reviews your images and reports, identifies the disease stage, and proposes a personalized non-surgical treatment plan. Reply within 48 hours.
Send MRI +49 160 5736643